organization · Reporting owner

BIOGEN INC.

Disclosed activity across 6 companies

Tapewire entity: 1675
SEC CIK: 0000875045

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Apellis Pharmaceuticals, Inc.APLS · Entity 47322	See footnotes	March 31, 2026	April 06, 2026
Bioverativ Inc.BIVV · Entity 168487	10% owner	February 01, 2017	February 01, 2017
Denali Therapeutics Inc.DNLI · Entity 1735	10% owner	September 22, 2020	September 28, 2020
REATA PHARMACEUTICALS INCRETA · Entity 12293	See footnotes	July 28, 2023	August 07, 2023
Sage Therapeutics, Inc.SAGE · Entity 77038	10% owner	December 31, 2020	January 11, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Apellis Pharmaceuticals, Inc.

Report date March 31, 2026 · Filed April 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance Holding disclosure · report date 2026-03-31 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0 F1: The reporting person entered into a Tender and Support Agreement, dated March 31, 2026 (the "Tender and Support Agreement") with respect to the shares of common stock, par value $0.0001 per share (the "Common Stock"), of Apellis Pharmaceuticals, Inc. (the "Issuer") held by each of (i) Morningside Venture Investments, Ltd., (ii) Cedric Francois, (iii) Gerald Chan, (iv) Alec Machiels, and (v) Pascal Deschatelets (each, a "Holder" and, collectively, the "Holders"). F2: By virtue of entering into the Tender and Support Agreement, dated March 31, 2026, with each of the Holders, the reporting person on this Form 3 may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act") with respect to the securities held by parties who continue to be bound by the Tender and Support Agreement, which such "group" beneficially owns (as defined in Section 13(d) of the Exchange Act), in the aggregate, more than 10% of the outstanding Common Stock. Pursuant to the Tender and Support Agreement, the Holders agreed to irrevocably and unconditionally appoint the reporting person, or any person designated by the reporting person, as its proxy and attorney-in-fact to vote such Holders' Common Stock for certain matters as set forth in the Tender and Support Agreement. F3: The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance Holding disclosure · report date 2026-03-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 0 F4: Each of Messrs Chan, Deschatelets, Francois and Machiels holds Restricted Stock Units ("RSUs") in the amount and on the terms reported on each of Messrs Chan, Deschatelets, Francois and Machiels' past and current Form 3 and Form 4 filings with respect to the Issuer, as amended. The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock underlying such RSUs and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee footnotes	Not disclosed	Reported balance Holding disclosure · report date 2026-03-31 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F5: Each of Messrs Chan, Deschatelets, Francois and Machiels holds options for Common Stock (the "Options"), which are currently outstanding and unexercised as of March 31, 2026, in the amount and on the terms reported on each of Messrs Chan, Deschatelets, Francois and Machiels' past and current Form 3 and Form 4 filings with respect to the Issuer, as amended. The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock underlying such Options and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act. F1: The reporting person entered into a Tender and Support Agreement, dated March 31, 2026 (the "Tender and Support Agreement") with respect to the shares of common stock, par value $0.0001 per share (the "Common Stock"), of Apellis Pharmaceuticals, Inc. (the "Issuer") held by each of (i) Morningside Venture Investments, Ltd., (ii) Cedric Francois, (iii) Gerald Chan, (iv) Alec Machiels, and (v) Pascal Deschatelets (each, a "Holder" and, collectively, the "Holders"). F2: By virtue of entering into the Tender and Support Agreement, dated March 31, 2026, with each of the Holders, the reporting person on this Form 3 may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act") with respect to the securities held by parties who continue to be bound by the Tender and Support Agreement, which such "group" beneficially owns (as defined in Section 13(d) of the Exchange Act), in the aggregate, more than 10% of the outstanding Common Stock. Pursuant to the Tender and Support Agreement, the Holders agreed to irrevocably and unconditionally appoint the reporting person, or any person designated by the reporting person, as its proxy and attorney-in-fact to vote such Holders' Common Stock for certain matters as set forth in the Tender and Support Agreement. F3: The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person entered into a Tender and Support Agreement, dated March 31, 2026 (the "Tender and Support Agreement") with respect to the shares of common stock, par value $0.0001 per share (the "Common Stock"), of Apellis Pharmaceuticals, Inc. (the "Issuer") held by each of (i) Morningside Venture Investments, Ltd., (ii) Cedric Francois, (iii) Gerald Chan, (iv) Alec Machiels, and (v) Pascal Deschatelets (each, a "Holder" and, collectively, the "Holders").

F2: By virtue of entering into the Tender and Support Agreement, dated March 31, 2026, with each of the Holders, the reporting person on this Form 3 may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act") with respect to the securities held by parties who continue to be bound by the Tender and Support Agreement, which such "group" beneficially owns (as defined in Section 13(d) of the Exchange Act), in the aggregate, more than 10% of the outstanding Common Stock. Pursuant to the Tender and Support Agreement, the Holders agreed to irrevocably and unconditionally appoint the reporting person, or any person designated by the reporting person, as its proxy and attorney-in-fact to vote such Holders' Common Stock for certain matters as set forth in the Tender and Support Agreement.

F3: The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.

F4: Each of Messrs Chan, Deschatelets, Francois and Machiels holds Restricted Stock Units ("RSUs") in the amount and on the terms reported on each of Messrs Chan, Deschatelets, Francois and Machiels' past and current Form 3 and Form 4 filings with respect to the Issuer, as amended. The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock underlying such RSUs and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.

F5: Each of Messrs Chan, Deschatelets, Francois and Machiels holds options for Common Stock (the "Options"), which are currently outstanding and unexercised as of March 31, 2026, in the amount and on the terms reported on each of Messrs Chan, Deschatelets, Francois and Machiels' past and current Form 3 and Form 4 filings with respect to the Issuer, as amended. The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock underlying such Options and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.

Bioverativ Inc.

Report date February 01, 2017 · Filed February 01, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-02-01 transaction · row 1 1 source row Row 1 · 2017-02-01 · Other · Disposed 107,975,968 · Balance 0 F1: Biogen Inc. distributed the shares to its shareholders on a pro rata basis in connection with the separation of the Issuer from Biogen Inc. on February 1, 2017. F2: On January 31, 2017, the 1,000 shares of common stock of the Issuer, issued and outstanding as of such date, were reclassified and subdivided into 107,975,968 shares resulting in the reporting person's ownership of a total of 107,975,968 shares of common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Biogen Inc. distributed the shares to its shareholders on a pro rata basis in connection with the separation of the Issuer from Biogen Inc. on February 1, 2017.

F2: On January 31, 2017, the 1,000 shares of common stock of the Issuer, issued and outstanding as of such date, were reclassified and subdivided into 107,975,968 shares resulting in the reporting person's ownership of a total of 107,975,968 shares of common stock.

Denali Therapeutics Inc.

Report date September 22, 2020 · Filed September 28, 2020

Jointly reported with Biogen MA Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Biogen MA Inc.	13,310,243	Reported balance Holding disclosure · report date 2020-09-22 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 13,310,243 F1: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

REATA PHARMACEUTICALS INC

Report date July 28, 2023 · Filed August 07, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance Holding disclosure · report date 2023-07-28 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0 F1: The reporting person entered into Voting and Support Agreements, dated July 28, 2023 (the "Support Agreements") with respect to the shares of class A common stock, par value $0.001 per share (the "Class A Shares"), of Reata Pharmaceuticals, Inc. (the "Issuer") and class B common stock, par value, $0.001 per share (the "Class B Shares" and, together with the Class A Shares, the "Reata Shares"), of the Issuer held by each of (i) J. Warren Huff, (ii) The 2021 JWH GRAT, (iii) R. Kent McGaughy, Jr., (iv) Lagos Trust, (v) Traweek Children's Trust, (vi) CPMG, Inc., (vii) William E. Rose; (viii) the Charles Henry Rose 2001 Trust, (ix) the John William Rose 2002 Trust, (x) Montrose Investments I, L.P., (xi) Montrose Investments GP, LLC, (xii) Evelyn P. Rose; (xiii) Evelyn P. Rose Fidelity SEP IRA, (xiv) Evelyn Potter Rose Survivor's Trust, (xv) Charles E. Gale and (xvi) an IRA created for Mr. Gale's benefit (each, a "Holder" and, collectively, the "Holders"). F2: The Class B Shares are convertible to Class A Shares on a one-to-one basis. By virtue of entering into Voting and Support Agreements, dated July 28, 2023, with each of the Holders, the reporting person on this Form 3 may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act") with respect to the securities held by parties who continue to be bound by the Support Agreements, which such "group" beneficially own (as defined in Section 13(d) of the Exchange Act), in the aggregate, more than 10% of the outstanding Class A Shares. Pursuant to the Support Agreements, the Holders agreed to irrevocably and unconditionally appoint the reporting person, or any person designated by the reporting person, as its proxy and attorney-in-fact to vote such Holders' Reata Shares. F3: The Support Agreements do not provide the reporting person with a pecuniary interest in the Class A Shares and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.
Class A common stockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance Holding disclosure · report date 2023-07-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 0 F4: Mr. Huff holds Restricted Stock Units ("RSUs") in the amount and on the terms reported on Mr. Huff''s Form 4 filings with respect to the Issuer, as amended. The Support Agreements do not provide the reporting person with a pecuniary interest in the Class A Shares underlying such RSUs and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee footnotes	Not disclosed	Reported balance Holding disclosure · report date 2023-07-28 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F5: Each of Messrs Huff, McGaughy, Jr. and Rose hold options for Class A Shares and Class B Shares (collectively, the "Options"), which are currently exercisable or exercisable within 60 days of the date hereof, in the amount and on the terms reported on each of Messrs Huff, McGaughty, Jr. and Rose's Form 4 filings with respect to the Issuer, as amended. The Support Agreements do not provide the reporting person with a pecuniary interest in the Class A Shares underlying such Options and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act. F1: The reporting person entered into Voting and Support Agreements, dated July 28, 2023 (the "Support Agreements") with respect to the shares of class A common stock, par value $0.001 per share (the "Class A Shares"), of Reata Pharmaceuticals, Inc. (the "Issuer") and class B common stock, par value, $0.001 per share (the "Class B Shares" and, together with the Class A Shares, the "Reata Shares"), of the Issuer held by each of (i) J. Warren Huff, (ii) The 2021 JWH GRAT, (iii) R. Kent McGaughy, Jr., (iv) Lagos Trust, (v) Traweek Children's Trust, (vi) CPMG, Inc., (vii) William E. Rose; (viii) the Charles Henry Rose 2001 Trust, (ix) the John William Rose 2002 Trust, (x) Montrose Investments I, L.P., (xi) Montrose Investments GP, LLC, (xii) Evelyn P. Rose; (xiii) Evelyn P. Rose Fidelity SEP IRA, (xiv) Evelyn Potter Rose Survivor's Trust, (xv) Charles E. Gale and (xvi) an IRA created for Mr. Gale's benefit (each, a "Holder" and, collectively, the "Holders"). F2: The Class B Shares are convertible to Class A Shares on a one-to-one basis. By virtue of entering into Voting and Support Agreements, dated July 28, 2023, with each of the Holders, the reporting person on this Form 3 may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act") with respect to the securities held by parties who continue to be bound by the Support Agreements, which such "group" beneficially own (as defined in Section 13(d) of the Exchange Act), in the aggregate, more than 10% of the outstanding Class A Shares. Pursuant to the Support Agreements, the Holders agreed to irrevocably and unconditionally appoint the reporting person, or any person designated by the reporting person, as its proxy and attorney-in-fact to vote such Holders' Reata Shares. F3: The Support Agreements do not provide the reporting person with a pecuniary interest in the Class A Shares and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person entered into Voting and Support Agreements, dated July 28, 2023 (the "Support Agreements") with respect to the shares of class A common stock, par value $0.001 per share (the "Class A Shares"), of Reata Pharmaceuticals, Inc. (the "Issuer") and class B common stock, par value, $0.001 per share (the "Class B Shares" and, together with the Class A Shares, the "Reata Shares"), of the Issuer held by each of (i) J. Warren Huff, (ii) The 2021 JWH GRAT, (iii) R. Kent McGaughy, Jr., (iv) Lagos Trust, (v) Traweek Children's Trust, (vi) CPMG, Inc., (vii) William E. Rose; (viii) the Charles Henry Rose 2001 Trust, (ix) the John William Rose 2002 Trust, (x) Montrose Investments I, L.P., (xi) Montrose Investments GP, LLC, (xii) Evelyn P. Rose; (xiii) Evelyn P. Rose Fidelity SEP IRA, (xiv) Evelyn Potter Rose Survivor's Trust, (xv) Charles E. Gale and (xvi) an IRA created for Mr. Gale's benefit (each, a "Holder" and, collectively, the "Holders").

F2: The Class B Shares are convertible to Class A Shares on a one-to-one basis. By virtue of entering into Voting and Support Agreements, dated July 28, 2023, with each of the Holders, the reporting person on this Form 3 may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act") with respect to the securities held by parties who continue to be bound by the Support Agreements, which such "group" beneficially own (as defined in Section 13(d) of the Exchange Act), in the aggregate, more than 10% of the outstanding Class A Shares. Pursuant to the Support Agreements, the Holders agreed to irrevocably and unconditionally appoint the reporting person, or any person designated by the reporting person, as its proxy and attorney-in-fact to vote such Holders' Reata Shares.

F3: The Support Agreements do not provide the reporting person with a pecuniary interest in the Class A Shares and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.

F4: Mr. Huff holds Restricted Stock Units ("RSUs") in the amount and on the terms reported on Mr. Huff''s Form 4 filings with respect to the Issuer, as amended. The Support Agreements do not provide the reporting person with a pecuniary interest in the Class A Shares underlying such RSUs and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.

F5: Each of Messrs Huff, McGaughy, Jr. and Rose hold options for Class A Shares and Class B Shares (collectively, the "Options"), which are currently exercisable or exercisable within 60 days of the date hereof, in the amount and on the terms reported on each of Messrs Huff, McGaughty, Jr. and Rose's Form 4 filings with respect to the Issuer, as amended. The Support Agreements do not provide the reporting person with a pecuniary interest in the Class A Shares underlying such Options and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.

Sage Therapeutics, Inc.

Report date December 31, 2020 · Filed January 11, 2021

Jointly reported with Biogen MA Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Biogen MA Inc.	6,241,473	Reported balance Holding disclosure · report date 2020-12-31 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 6,241,473 F1: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SANGAMO THERAPEUTICS, INC

Report date September 26, 2023 · Filed September 28, 2023

Jointly reported with Biogen MA Inc.

Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Biogen MA Inc.	17,652,466	Reported balance After 2023-09-26 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-09-26 · Sale · Disposed 6,000,000 · Balance 17,652,466 F1: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 26, 2023 Filed Sep 28, 2023 21:30 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	6,000,000	$0.50	$3,000,000.00	Disclosure SEC source: 0000899243-23-019611 · doc4.xml · nonDerivative · entry 1 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 17,652,466 F1 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
August 30, 2022 Filed Aug 31, 2022 23:03 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	100,000	$5.27	$526,520.00	Disclosure SEC source: 0000899243-22-030136 · doc4.xml · nonDerivative · entry 2 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 23,652,466 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1235 to $5.49, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
August 29, 2022 Filed Aug 31, 2022 23:03 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	400,000	$5.33	$2,130,720.00	Disclosure SEC source: 0000899243-22-030136 · doc4.xml · nonDerivative · entry 1 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 23,752,466 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.205 to $5.475, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
December 28, 2021 Filed Dec 30, 2021 22:12 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	2,764	$8.51	$23,521.92	Disclosure SEC source: 0000875045-21-000061 · wf-form4_164090233143707.xml · nonDerivative · entry 1 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 24,152,466 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.53, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
December 27, 2021 Filed Dec 28, 2021 13:11 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	600	$8.56	$5,136.00	Disclosure SEC source: 0000875045-21-000060 · wf-form4_164069706538898.xml · nonDerivative · entry 2 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 24,155,230 F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
December 23, 2021 Filed Dec 28, 2021 13:11 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	81,187	$8.55	$694,530.43	Disclosure SEC source: 0000875045-21-000060 · wf-form4_164069706538898.xml · nonDerivative · entry 1 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 24,155,830 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.65, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
December 09, 2021 Filed Dec 10, 2021 21:08 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	23,660	$8.56	$202,541.43	Disclosure SEC source: 0000875045-21-000059 · wf-form4_163917049537863.xml · nonDerivative · entry 1 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 24,237,017 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.71, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
December 08, 2021 Filed Dec 9, 2021 21:08 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	75,814	$8.64	$654,828.26	Disclosure SEC source: 0000875045-21-000058 · wf-form4_163908412073554.xml · nonDerivative · entry 2 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 24,260,677 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.735, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
December 07, 2021 Filed Dec 9, 2021 21:08 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	52,178	$8.52	$444,436.55	Disclosure SEC source: 0000875045-21-000058 · wf-form4_163908412073554.xml · nonDerivative · entry 1 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 24,336,491 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.595, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
December 02, 2021 Filed Dec 3, 2021 21:09 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	1,874	$8.51	$15,942.87	Disclosure SEC source: 0000875045-21-000057 · wf-form4_163856574488863.xml · nonDerivative · entry 2 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 24,388,669 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.515, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
December 01, 2021 Filed Dec 3, 2021 21:09 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	730	$8.52	$6,223.18	Disclosure SEC source: 0000875045-21-000057 · wf-form4_163856574488863.xml · nonDerivative · entry 1 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 24,390,543 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.54, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
November 26, 2021 Filed Nov 30, 2021 21:20 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	28,884	$8.60	$248,434.17	Disclosure SEC source: 0000875045-21-000055 · wf-form4_163830723294834.xml · nonDerivative · entry 1 BIOGEN INC. · CIK 0000875045 · 10% owner Biogen MA Inc. · CIK 0001810387 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biogen MA Inc. Disclosed balance after: 24,391,273 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.74, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. Read SEC document
February 01, 2017 Filed Feb 1, 2017 22:21 UTC	Bioverativ Inc. BIVV · Entity 168487	OtherCommon Stock	107,975,968	$0.00	$0.00	Disclosure SEC source: 0001127602-17-003387 · form4.xml · nonDerivative · entry 1 BIOGEN INC. · CIK 0000875045 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Biogen Inc. distributed the shares to its shareholders on a pro rata basis in connection with the separation of the Issuer from Biogen Inc. on February 1, 2017. F2 · shares: On January 31, 2017, the 1,000 shares of common stock of the Issuer, issued and outstanding as of such date, were reclassified and subdivided into 107,975,968 shares resulting in the reporting person's ownership of a total of 107,975,968 shares of common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.